Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 15, 2026, Pyxis Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders at 10:00 a.m. Eastern Daylight Time in a virtual format via live audio webcast (the "Annual Meeting"). As of April 20, 2026, the Company's record date, there were a total of 62,855,464 shares of common stock outstanding and entitled to vote at the Annual Meeting. At the beginning of the Annual Meeting, 47,302,035 shares of common stock were present virtually, in person or by proxy, and, therefore, a quorum was present. Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.

Proposal One: Election of Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger as Class II Directors

Mr. Thomas Civik, Dr. Freda Lewis-Hall, M.D. and Mr. Michael A. Metzger were elected to serve as Class II directors to hold office until the Company's 2029 Annual Meeting of Stockholders and until the election and qualification of their successors. Votes were cast as follows:

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following vote: